Papillary Thyroid CarcinomaNCT07302672
Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma
A study testing Humanistic Continuing Care via WeChat in people with Papillary Thyroid Carcinoma, run by Ming-an Yu at 1 site in China.
Trial summary
The goal of this clinical trial is to test whether human-centered nursing care lowers emotional distress and improves quality of life for people who are awake during thyroid thermal ablation. The procedure uses local anesthesia, so participants remain awake and may feel tense. Read more about this study
- Who is it for?
- Ages 16 to 60 years
- Conditions the study is for
- Papillary Thyroid Carcinoma
- What is being tested?
- Humanistic Continuing Care via WeChat
- Type of treatment
- Surgery or procedure, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 108 participants
- Where
- 1 siteChina
- Study dates
- 15 Dec 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 60 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Age 16-60 years; scheduled for thyroid thermal ablation
- Papillary thyroid carcinoma (PTC)
- Number of target lesions <= 3
- Largest lesion diameter <= 2 cm; clinical stage T1N0M0 by imaging
- Awake and able to cooperate under local anesthesia
- Owns a smartphone and can use WeChat
Who cannot join
- Serious medical comorbidities or cognitive impairment that precludes participation
- Prior thyroid surgery or thermal ablation
- Unwilling or unable to join the WeChat group or complete postoperative follow-up
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
China-Japan Friendship Hospital
Beijing
ming-an yu, 84205756, yma301@163.com
yan li, 84205756, 497059493@qq.com
About this study
The goal of this clinical trial is to test whether human-centered nursing care lowers emotional distress and improves quality of life for people who are awake during thyroid thermal ablation. The procedure uses local anesthesia, so participants remain awake and may feel tense. Human-centered care focuses on emotional support, clear communication, comfort, and follow-up, and it may improve the experience and recovery for patients.
The main questions are:
Read more
Does human-centered nursing care reduce emotional distress levels in patients undergoing thyroid thermal ablation?
Does human-centered nursing care improve patient quality of life after thyroid thermal ablation?
If there is a comparison group: Researchers will compare human-centered nursing care to usual nursing care to see if human-centered care leads to lower emotional distress and higher quality of life.
Participants will:
Receive either human-centered nursing care or usual nursing care.
Complete questionnaires before, during, and after the procedure to measure emotional distress, quality of life, pain, and satisfaction with care.
Have their vital signs and quality of life tracked during and after the procedure.
Have their adherence to care plans and any complications monitored.
The main outcomes are emotional distress levels and quality of life. Other outcomes include pain and vital signs during the procedure, satisfaction with care, and complication rates. Results may guide better care for people undergoing small, minimally invasive treatments while awake.
- Conditions
- Papillary Thyroid Carcinoma
- Being tested
- Humanistic Continuing Care via WeChat, Usual Care (No Structured WeChat Program)
- Keywords
- papillary thyroid carcinoma, thermal ablation, humanistic care, continuity care, Wechat, anxiety, quality of life
- Medical subject headings
- Thyroid Cancer, Papillary, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Humanistic Continuing Care via WeChatBehavioural
Description: Structured, humanistic peri-operative nursing program delivered through WeChat in addition to routine care. Components: pre-procedure needs assessment and expectation setting; brief coping skills coaching (e.g., paced breathing); intra-procedure step-by-step explanations, reassurance, and comfort measures; post-procedure education, recovery guidance, and psychosocial support; symptom monitoring with red-flag escalation; medication/wound-care and appointment reminders; on-demand messaging during service hours; optional caregiver engagement.
Delivery \& Schedule: Nurse-led. One pre-procedure session; intra-procedure support on the day of ablation; post-procedure WeChat check-ins at least weekly plus on-demand messaging for 12 weeks. Fidelity tracked via standardized checklists.
Arm(s): Experimental - Humanistic Continuing Care via WeChat.
Usual Care (No Structured WeChat Program)Procedure or surgery
Participants receive standard peri-operative nursing and institutional discharge materials, including routine pre-procedure counseling, standard intra-procedure monitoring, printed/posted instructions for home care, and follow-up per usual practice (e.g., clinic visit or routine phone call). They may contact the clinic using standard channels as needed, but there is no scheduled, structured WeChat outreach or humanistic continuing-care protocol.
| Study group | Role | What they receive |
|---|---|---|
| Humanistic Continuing Care via WeChat | Experimental | Not described Receives: Behavioral: Humanistic Continuing Care via WeChat |
| Usual Care (No Structured WeChat Program) | Active comparator | Not described Receives: Procedure: Usual Care (No Structured WeChat Program) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in emotion distress from baseline to post-procedure (HADS)
Measured: From enrollment to the end of treatment at 3 months
Change in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores from baseline to 3 months
Measured: From enrollment to the end of treatment at 3 months
Change in Thyroid Cancer-Specific Quality of Life Questionnaire scores from baseline to 3 months
Measured: From enrollment to 3 months after end of treatment
Secondary outcomes (2)
Intraoperative pain intensity (Visual Analog Scale)
Pain intensity during the procedure will be assessed using a Visual Analog Scale (VAS; 0-100 mm, where 0 indicates no pain and 10 indicates the worst imaginable pain). A single VAS score will be recorded during the intraoperative period.
Measured: Intraoperative period (during the procedure)
Patient satisfaction with nursing care (Newcastle Satisfaction with Nursing Scale, NSNS)
Measured: Postoperative Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study start15 Dec 2025
- Primary completion30 Jun 2026
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Papillary Thyroid CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 108 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ming-an Yu
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Ming-an Yu, China-Japan Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07302672
- Sponsor's protocol ID
- 2509008
- Status last verified
- Dec 2025
- First submitted
- 29 Nov 2025
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Undecided at this time; a final decision about IPD sharing will be made after publication in consultation with the institution's data governance and ethics committees.
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma
- ClinicalTrials.gov ID
- NCT07302672
- Acronym / sponsor ID
- 2509008
- Conditions
- Papillary Thyroid Carcinoma
- Keywords
- papillary thyroid carcinoma, thermal ablation, humanistic care, continuity care, Wechat, anxiety, quality of life
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 108 participants (estimated)
- Lead sponsor
- Ming-an YuUniversity, hospital or other
- Study start
- 15 Dec 2025 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test whether human-centered nursing care lowers emotional distress and improves quality of life for people who are awake during thyroid thermal ablation. The procedure uses local anesthesia, so participants remain awake and may feel tense. Human-centered care focuses on emotional support, clear communication, comfort, and follow-up, and it may improve the experience and recovery for patients.
The main questions are:
Does human-centered nursing care reduce emotional distress levels in patients undergoing thyroid thermal ablation?
Does human-centered nursing care improve patient quality of life after thyroid thermal ablation?
If there is a comparison group: Researchers will compare human-centered nursing care to usual nursing care to see if human-centered care leads to lower emotional distress and higher quality of life.
Participants will:
Receive either human-centered nursing care or usual nursing care.
Complete questionnaires before, during, and after the procedure to measure emotional distress, quality of life, pain, and satisfaction with care.
Have their vital signs and quality of life tracked during and after the procedure.
Have their adherence to care plans and any complications monitored.
The main outcomes are emotional distress levels and quality of life. Other outcomes include pain and vital signs during the procedure, satisfaction with care, and complication rates. Results may guide better care for people undergoing small, minimally invasive treatments while awake.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Humanistic Continuing Care via WeChat | Experimental | Behavioral: Humanistic Continuing Care via WeChat |
| Usual Care (No Structured WeChat Program) | Active comparator | Procedure: Usual Care (No Structured WeChat Program) |
Who may qualify
- Ages
- 16 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (6 listed)
- Age 16-60 years; scheduled for thyroid thermal ablation
- Papillary thyroid carcinoma (PTC)
- Number of target lesions <= 3
- Largest lesion diameter <= 2 cm; clinical stage T1N0M0 by imaging
- Awake and able to cooperate under local anesthesia
Key exclusion criteria (3 listed)
- Serious medical comorbidities or cognitive impairment that precludes participation
- Prior thyroid surgery or thermal ablation
- Unwilling or unable to join the WeChat group or complete postoperative follow-up
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Humanistic Continuing Care via WeChatDescription: Structured, humanistic peri-operative nursing program delivered through WeChat in addition to routine care. Components: pre-procedure needs assessment and expectation setting; brief coping skills coaching (e.g., paced breathing); intra-procedure step-by-step explanations, reassurance, and comfort measures; post-procedure education, recovery guidance, and psychosocial support; symptom monitoring with red-flag escalation; medication/wound-care and appointment reminders; on-demand messaging during service hours; optional caregiver engagement. Delivery \& Schedule: Nurse-led. One pre-procedure session; intra-procedure support on the day of ablation; post-procedure WeChat check-ins at least weekly plus on-demand messaging for 12 weeks. Fidelity tracked via standardized checklists. Arm(s): Experimental - Humanistic Continuing Care via WeChat. | Behavioural | Humanistic Continuing Care via WeChat |
| Usual Care (No Structured WeChat Program)Participants receive standard peri-operative nursing and institutional discharge materials, including routine pre-procedure counseling, standard intra-procedure monitoring, printed/posted instructions for home care, and follow-up per usual practice (e.g., clinic visit or routine phone call). They may contact the clinic using standard channels as needed, but there is no scheduled, structured WeChat outreach or humanistic continuing-care protocol. | Procedure or surgery | Usual Care (No Structured WeChat Program) |
Primary outcome
Change in emotion distress from baseline to post-procedure (HADS)
Time frame: From enrollment to the end of treatment at 3 months
Change in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores from baseline to 3 months
Time frame: From enrollment to the end of treatment at 3 months
Change in Thyroid Cancer-Specific Quality of Life Questionnaire scores from baseline to 3 months
Time frame: From enrollment to 3 months after end of treatment
2 secondary outcomes
Intraoperative pain intensity (Visual Analog Scale)
Time frame: Intraoperative period (during the procedure)
Patient satisfaction with nursing care (Newcastle Satisfaction with Nursing Scale, NSNS)
Time frame: Postoperative Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Individual participant dataSharing planned: Undecided. Undecided at this time; a final decision about IPD sharing will be made after publication in consultation with the institution's data governance and ethics committees.
Related trials for Papillary Thyroid Carcinoma
Recruiting
Active Surveillance of Papillary Thyroid Microcarcinoma
Papillary Thyroid Microcarcinoma
RecruitingObservational study
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY
Papillary Thyroid Cancer
Not yet recruitingObservational study
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
RecruitingObservational study
Studies on Tumors of the Thyroid
Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer
Active, not recruitingPhase 3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Differentiated Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Humanistic Continuing Care via WeChat in people with Papillary Thyroid Carcinoma, run by Ming-an Yu at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact ming-an yu, MD (84205756, yma301@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in emotion distress from baseline to post-procedure (HADS) (time frame: From enrollment to the end of treatment at 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.